Adverse Effects | Topics

 
FDA Issues Complete Response Letter to Plinabulin Application for Prevention of Chemotherapy-Induced Neutropenia
December 02, 2021

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21, 2021

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

FDA Approves Luspatercept to Treat Beta Thalassemia–Associated Anemia
November 08, 2019

The agency approved the first and only FDA-approved erythroid maturation agent to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Researchers Make Anemia Discovery That May Provide New Targets for Therapy
February 05, 2018

A new study has revealed that the amount of iron in the blood affects the amount of the Scribble protein, which appears to control receptors that create new red blood cells.

New Insights Into Sickle Cell Disease Point to Novel Treatment Paradigms
January 29, 2018

Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.